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Human polyomavirus JC is the causative agent of a deadly form of sudden onset dementia, progressive multifocal leuko-
coencephalopathy (PML). PML is highly prevalent in immunodeﬁcient populations, specially those undergoing chemotherapy,
immunosuppressive treatments for autoimmune conditions, and HIV-1/AIDS patients. In fact, before the highly active
antiretroviral therapy (HAART) regimens became available, PML was a leading cause of death in HIV-1 seropositive individuals.
However, patients under HAART show increased survival times with better prognoses. In this report we described the main
diﬀerences between PMLbeforeandaftertheHAART era;highlightingthenewpatternsofpresentation,theneurotropismofother
humanpolyomaviruses,andtheincreased prevalence ofimmunereconstitutioninﬂammatorysyndrome(IRIS),asa complication
of PML in patients under HAART. Lastly, we propose a revised classiﬁcationof human poliomavirus-associatedcerebral disorders
that may reﬂect more accurately what clinicians encounter in their everyday practice.
Since the introduction of highly active antiretroviral therapy
(HAART), morbidity and mortality secondary to oppor-
tunistic disorders in patients infected with HIV-1 have
signiﬁcantly decreased [1]. However, the prevalence of
neurocognitive impairment has remained steady and still
occurs in up to 50% of HIV-1/AIDS patients [2]. Moreover,
there is a growing number of reports depicting atypical
presentations of previously well-characterized brain disor-
ders [3], as well as emerging pathologies associated with
the reactivation of the immune system [4], both of which
represent diagnostic and therapeutic challenges to experts in
the ﬁelds of neurology and infectious diseases.
Human polyomaviruses JC and BK (named after the
two initials of the ﬁrst patients in which the viruses were,
respectively, isolated) rarely cause disease, except for patients
with an underlying immunocompromise. JC virus (JCV)
is the causative agent of a fatal demyelinating disorder
termed progressive multifocal leukoencephalopathy (PML)
[5]. PML is an unusual source of cognitive,motor, and visual
impairments with rapid death in the absence of HAART.
This disorder is recognized by multiple foci ofdemyelination
aﬀecting the subcortical white matter, and by pathological
ﬁndings that include giant astrocytes and olygodendrocytes
with enlarged nuclei. Similarly, BK virus (BKV) is known
to cause hemorrhagic cystitis and polyomavirus-associated
nephropathy (PVAN), especially in kidney transplant recipi-
ents and in patients undergoing chemotherapy.
Before HAART became widely available, there was no
treatment for polyomavirus-associated disorders, and death
from PML occurred as early as 3 months after diagnosis [6].
The one-year survival of patients with PML has substantially
increased over the last decade,from 0%–30%before HAART
became available to 38%–62% in the post-HAART era
[7–10]. Interestingly, while the prognosis and survival of2 Pathology Research International
patients with PML have greatly increased [11], we have
recently observed noticeable changes in their patterns of
presentation, which are noteworthy of being thoroughly
discussed.
First, ourexperience mainly withBrazilianAIDSpatients
has recently demonstrated how prevalent PML could be as
a neurological complication in HIV-1 seropositive patients,
as PML cases are only exceeded by those of cerebral
toxoplasmosis, cryptococcal meningoencephalitis, and CNS
tuberculosis [12]. To date, the presentation of JCV-driven
CNS manifestation is not restricted to multiple foci in the
subcorticalwhitematter[13],butalsotomultipleorunifocal
lesions in a variety of sites, including the white matter of the
cerebellar peduncles[8], the deep grey matter [14], neuronal
cells in the cerebellum (granule cell neuronopathy) [3], or
the cortical pyramidal neurons in the gray/white matter
interface, recently termedasJCVencephalopathy[15].These
novel presentations of polyomavirus-associated diseases
occur primarily in patients under HAART and highlight
the relevance of performing biopsies and molecular studies
to genotype and identify mutations altering the behavior
and tropism of the JC virus in all HIV-1/AIDS patients
with radiological observable brain lesions [13, 16, 17].
Noteworthy, the JCV-associated spectrum of neurological
diseases currently constitutes a variety of syndromes recently
classiﬁed as classic PML, inﬂammatory progressive multi-
focal leukoencephalopathy, JCV granule cell neuronopathy,
and JCV meningitis [18]. As a result, we would like to
propose a revision on the diagnostic criteria for PML as
well as a complementary classiﬁcation based on the number
and location of the lesions (multifocal versus unifocal), and
the nature of the clinical presentation—classic (subcortical
white matter lesions) versus variant (involvement of the
cerebellar peduncles and/or brainstem) (Figure 1(a)), which
maybemoresuitabletowhatpractitionersencounterintheir
everyday practice.
Furthermore, we have noticed a growing number of
cases reporting worsening of PML after introduction of
HAART [19–21]. This paradoxical worsening of PML weeks
or months after starting HAART is due to an uncontrolled
inﬂammatory responseoftheimmunesystemtoopportunis-
tic pathogens and to certain tumors. The so-called “immune
reconstitution syndrome” or “immune restoration disease”
[4], when observed in the context of PML, can lead to rapid
death in the absence of intervention; however, a consensus
still needs to be reached about the proper measurements to
take in this scenario (Figure 1(b))[ 22].
Lastly, we would like to comment about the newly
discovered neurotropism of BKV [23]. Althoughthe recently
characterized human polyomaviruses (KI, WU, WUV) have
not yet been demonstrated to cause PML [24], there had
been four cases of BKV-associated neurological compromise
in AIDS patients reported in the literature; all of them
accompanied by renal involvement and resulting in death
[25–27]. Nevertheless, we have recently reported a case
of BKV meningoencephalitis contained within the CNS,
and with recovery under HAART [28]. Even when the
causes of BKV neurotropism have not been established
yet, we propose that this polyomavirus may be further
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Figure 1: (a) Left, image shows classical PML, described as
multiple foci of demyelination in the subcortical white matter.
Right, image shows variant PML, described as one or multiple
foci in regions outside the subcortical white matter, for example,
the cerebellar peduncles (arrows). (b) Course and evolution of an
AIDS patient with PML under HAART. From left to right, ﬁrst
column shows MRI with abnormal signal in the subcortical area
of bilateral frontal lobes; diagnosis is conﬁrmed by histopathology
and treatment with HAART is started. The second column shows
signiﬁcant improvement under HAART. The third column shows
worsening of the lesions three months after introduction of
HAART (immune reconstitution syndrome). The fourth column
shows improvement of the lesions after empiric treatment with
intravenous immunoglobulin (IVIG).
investigated as an etiologic agent of neurological disease in
AIDSpatients,especially when more frequentetiologieshave
been discarded.
In conclusion, all the aforementioned data suggest that
human polyomaviruses are playing a major role in the post-
HAART era, and nothing but a multidisciplinary study of
theirbiologyandthepathogenesisoftheirassociateddiseases
will lead to more eﬃcacious interventions.
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